Bausch Health Companies Inc. financial data

Symbol
BHC on NYSE
Industry
Pharmaceutical Preparations
Location
2150 St. Elzear Blvd. West, Laval, Quebec, Quebec, Canada
State of incorporation
NJ
Fiscal year end
December 31
Former names
Valeant Pharmaceuticals International, Inc. (to 7/3/2018), BIOVAIL Corp (to 9/27/2010), BIOVAIL CORP INTERNATIONAL (to 4/7/2010), BIOVAIL CORPORATION INTERNATIONAL (to 1/5/2001)
Latest financial report
Oct 31, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 123 % +9.39%
Quick Ratio 36.7 % +22%
Debt-to-equity -2.41K % +22.2%
Return On Equity 98.2 %
Return On Assets -0.66 % +82.1%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 368M shares +0.71%
Common Stock, Shares, Outstanding 368M shares +0.73%
Entity Public Float 2.42B USD -3.53%
Common Stock, Value, Issued 10.5B USD +0.66%
Weighted Average Number of Shares Outstanding, Basic 368M shares +0.82%
Weighted Average Number of Shares Outstanding, Diluted 368M shares +0.82%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 9.47B USD +10.9%
Costs and Expenses 8.12B USD -0.65%
Operating Income (Loss) 1.35B USD +270%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -49M USD +93.4%
Income Tax Expense (Benefit) 168M USD -28.2%
Net Income (Loss) Attributable to Parent -178M USD +81.5%
Earnings Per Share, Basic -0.48 USD/shares +81.8%
Earnings Per Share, Diluted -0.48 USD/shares +81.8%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 719M USD -5.4%
Inventory, Net 1.66B USD +30.1%
Assets, Current 5.35B USD +6%
Deferred Income Tax Assets, Net 2.19B USD -0.05%
Property, Plant and Equipment, Net 1.79B USD +12.9%
Operating Lease, Right-of-Use Asset 185M USD -16.3%
Intangible Assets, Net (Excluding Goodwill) 5.65B USD -16%
Goodwill 11.2B USD -0.14%
Other Assets, Noncurrent 389M USD +18.6%
Assets 26.5B USD -1.94%
Accounts Payable, Current 667M USD +17.2%
Accrued Liabilities, Current 3.39B USD +8.56%
Liabilities, Current 4.51B USD +6.68%
Deferred Income Tax Liabilities, Net 169M USD -20.7%
Operating Lease, Liability, Noncurrent 148M USD -19.6%
Other Liabilities, Noncurrent 805M USD +11.7%
Liabilities 26.8B USD -1.89%
Accumulated Other Comprehensive Income (Loss), Net of Tax -1.95B USD +5.07%
Retained Earnings (Accumulated Deficit) -9.92B USD -1.83%
Stockholders' Equity Attributable to Parent -1.17B USD +0.51%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest -242M USD -2.98%
Liabilities and Equity 26.5B USD -1.94%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities 211M USD +37%
Net Cash Provided by (Used in) Financing Activities -340M USD -139%
Net Cash Provided by (Used in) Investing Activities -73M USD +6.41%
Common Stock, Shares, Issued 368M shares +0.73%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -207M USD -245%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 750M USD -3.85%
Deferred Tax Assets, Valuation Allowance 2.49B USD +13.3%
Deferred Tax Assets, Gross 4.55B USD +4%
Operating Lease, Liability 209M USD -10.7%
Payments to Acquire Property, Plant, and Equipment 82M USD +74.5%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -74M USD +90.1%
Lessee, Operating Lease, Liability, to be Paid 251M USD -12.5%
Property, Plant and Equipment, Gross 3.79B USD +7.67%
Operating Lease, Liability, Current 61M USD +22%
Lessee, Operating Lease, Liability, to be Paid, Year Two 54M USD +10.2%
Lessee, Operating Lease, Liability, to be Paid, Year One 74M USD +17.5%
Operating Lease, Weighted Average Discount Rate, Percent 0.07 pure +15.4%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 42M USD -20.8%
Lessee, Operating Lease, Liability, to be Paid, Year Three 35M USD -16.7%
Unrecognized Tax Benefits 918M USD +4.2%
Lessee, Operating Lease, Liability, to be Paid, Year Four 29M USD -19.4%
Deferred Tax Assets, Net of Valuation Allowance 2.3B USD -2.38%
Share-based Payment Arrangement, Expense 38M USD +31%